Prophylactic Use of Hydroxycobolamin in Vasoplegic Syndrome in Adult Patients Undergoing Cardiopulmonary Bypass
Status:
Completed
Trial end date:
2023-11-27
Target enrollment:
Participant gender:
Summary
Several studies have described the use of alternative drugs as methylene blue (MB) (3) other
than the standard limited options of the use of vasopressors and systemic corticosteroids (4)
especially in the face of increasing incidence of vasoplegic syndrome. Hydroxycobolamin (HCO)
has been used for treating cyanide poisoning for more than 40 years. Persistant and
significant hypertension occurred as a result of the ability of (HCO) to bind nitric oxide
(NO) to form nitrocobalamin.
In this prospective randomized controlled trial, we hypothesized that the prophylactic use of
HCO in high risk patients after CPB may decrease the incidence of vasoplegia.